Ola Lindén
1 – 38 of 38
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Targeted Alpha Therapy, an Emerging Class of Cancer Agents : A Review
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
(
- Contribution to journal › Article
- 2015
-
Mark
Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women - a Swedish Lymphoma Registry study.
(
- Contribution to journal › Article
-
Mark
Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
2015) In European Journal of Haematology(
- Contribution to journal › Article
-
Mark
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.
(
- Contribution to journal › Article
- 2013
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
(
- Contribution to journal › Article
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
(
- Contribution to journal › Article
-
Mark
90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Diversity in antibody-based approaches to non-Hodgkin lymphoma
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry
(
- Contribution to journal › Article
-
Mark
90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma First Results from an International Phase II Clinical Trial
(
- Contribution to journal › Published meeting abstract
-
Mark
Extracorporeal techniques for improving radioimmunotherapy of disseminated malignant tumors
2010)(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2009
-
Mark
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
(
- Contribution to journal › Article
-
Mark
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib.
(
- Contribution to journal › Letter
- 2008
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article
-
Mark
Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy.
(
- Contribution to journal › Article
- 2007
-
Mark
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray"
(
- Contribution to journal › Scientific review
-
Mark
Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread
(
- Contribution to journal › Article
-
Mark
Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.
(
- Contribution to journal › Article
-
Mark
Parametric images of antibody pharmacokinetics based on serial quantitative whole-body imaging and blood sampling
(
- Contribution to journal › Article
- 2006
-
Mark
Clinical applications of newer radionuclide therapies
(
- Contribution to journal › Article
- 2005
-
Mark
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab.
(
- Contribution to journal › Article
-
Mark
Radioimmunoterapi ved non-Hodgkins lymfom
(
- Contribution to journal › Article
-
Mark
Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma.
(
- Contribution to journal › Article
- 2004
-
Mark
Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab
(
- Contribution to journal › Letter
- 2003
-
Mark
Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients.
(
- Contribution to journal › Article
- 2002
-
Mark
Single tumor cell uptake and dosimetry of technetium-99m Fab ' anti-CD22 in low-grade B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
(
- Contribution to journal › Article
-
Mark
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
(
- Contribution to journal › Article
- 2001
-
Mark
Durable response to 90-yttrium-Epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule
(
- Contribution to journal › Article
- 1999
-
Mark
Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
(
- Contribution to journal › Article
- 1996
-
Mark
High-grade non-Hodgkin's lymphoma stage I. A retrospective study of treatment, outcome and prognostic factors in 213 patients
(
- Contribution to journal › Article
- 1988
-
Mark
Lymphocyte subpopulations and lymphokine production in children with constitutional aplastic anemia
(
- Contribution to journal › Article